{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:45:07Z","timestamp":1757781907381,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Evidence regarding the mortality benefit of implantable cardioverter defibrillator (ICD) non-ischemic dilated cardiomyopathy (NIDCM) is inconsistent. The most recent randomized study, the DANISH trial, did not find improved outcomes with ICD. However, based on previous studies and meta-analyses, current guidelines still highly recommend ICD implantation in NIDCM patients. The introduction of novel medications for heart failure improved the clinical outcome dramatically. We aimed in this study to evaluate the effect of Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and sodium-glucose transport protein 2 inhibitors (SGLT2i) on the mortality benefit of ICD in NIDCM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a previous metanalysis algorithm and added an updated comprehensive literature search in PubMed for randomized control trials that examined the mortality benefit of ICD in NIDCM vs. optimal medical treatment. The primary outcome included death from any cause. We did a meta-regression analysis to search for a single independent factor affecting mortality. Using previous data, we evaluated the theoretical effect of ICD implementation on patients treated with SGLT2 inhibitors and ARNi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No new articles were added to the results of the previous meta-analysis. 2,622 patients with NIDCM from 5 cohort studies published between 2002 and 2016 were included in the analysis. 50% of them underwent ICD implantation for primary prevention of sudden cardiac death, and 50% did not. ICD was associated with a significantly decreased risk for death from any cause compared to control (OR\u2009=\u20090.79, 95%CI: 0.66\u20130.95, <jats:italic>p<\/jats:italic>\u2009=\u20090.01, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%). The theoretical addition of ARNi and the SGLT2 inhibitor dapagliflozin did not change the significant mortality effect of ICD (OR\u2009=\u20090.82, 95%CI: 0.7\u20130.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%) and (OR\u2009=\u20090.82, 95%CI: 0.7\u20130.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%). A meta-regression revealed no association between death from any cause and left bundle branch block (LBBB), use of amiodarone, use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers, year initiated enrollment, and the year ended enrollment (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with NIDCM, the addition of ARNi and SGLT2i did not affect the mortality advantages of ICD for primary prevention.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO registry number<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier: CRD42023403210.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1192101","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T09:37:37Z","timestamp":1684748257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Yotam","family":"Kolben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruria","family":"Hirsh Raccah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivelin","family":"Koev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Luria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Offer","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitschak","family":"Biton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1111\/j.1540-8159.2009.02382.x","article-title":"Sudden cardiac death in dilated cardiomyopathies","volume":"32","author":"Hamilton","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"H2451","DOI":"10.1152\/ajpheart.00770.2011","article-title":"Mechanisms of ventricular arrhythmias: a dynamical systems-based perspective","volume":"302","author":"Cherry","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators","volume":"341","author":"Buxton","year":"1999","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"27","author":"McDonagh","year":"2021","journal-title":"Eur Heart J Aug"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e12253","DOI":"10.1111\/1755-5922.12253","article-title":"Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"35","author":"Akel","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"","journal-title":"BMJ. Oct"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.cir.0000012350.99718.ad","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT)","volume":"105","author":"B\u00e4nsch","year":"2002","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/s0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2013AMIOVIRT","volume":"41","author":"Strickberger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamacardio.2017.0630","article-title":"Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis","volume":"2","author":"Al-Khatib","year":"","journal-title":"JAMA Cardiol Jun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","article-title":"Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis","volume":"104","author":"Beggs","year":"2018","journal-title":"Heart"},{"key":"B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.121.056072","article-title":"Long-term follow-up of DANISH (the danish study to assess the efficacy of ICDs in patients with nonischemic systolic heart failure on mortality)","volume":"145","author":"Yafasova","year":"2022","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.hrthm.2021.04.017","article-title":"Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention","volume":"18","author":"S\u00e1nchez-Somonte","year":"2021","journal-title":"Heart Rhythm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ahj.2019.10.020","article-title":"Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI","volume":"221","author":"Elming","year":"2020","journal-title":"Am Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.jcmg.2018.10.032","article-title":"Microvascular dysfunction in dilated cardiomyopathy: a quantitative stress perfusion cardiovascular magnetic resonance study","volume":"12","author":"Gulati","year":"2019","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1192101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T09:37:40Z","timestamp":1684748260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1192101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2023.1192101"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1192101","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1192101"}}